Trace element associated reduction of norleucine and norvaline accumulation during oxygen limitation in a recombinant Escherichia coli fermentation

Microbial Cell Factories

Volumn 12, Issue 1, 2013, Pages

  Biermann, Michael ^a   Linnemann, Julia ^a   Knüpfer, Uwe ^a   Vollstädt, Sebastian ^a   Bardl, Bettina ^a   Seidel, Guido ^b   Horn, Uwe ^a  

^a HANS KNÖLL INSTITUTE   (Germany)

^b Wacker Biotech GmbH   (Germany)

Author keywords

Bioprocess design; Escherichia coli; Norleucine; Norvaline; Protein biopharmaceutical; Recombinant antibody; Scale down; Scale up; Trace elements

Indexed keywords

AMINO ACID; ANTIBODY; ANTIBODY DOMAIN B10; FORMATE DEHYDROGENASE; GLUCOSE; HYDROGEN; MOLYBDENUM; NICKEL; NORLEUCINE; NORVALINE; OXYGEN; SELENIUM; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; AMINO ACID SYNTHESIS; ARTICLE; BACTERIAL GROWTH; BIOMASS PRODUCTION; CELL DENSITY; CONTROLLED STUDY; DRUG MANUFACTURE; ENVIRONMENTAL STRESS; ESCHERICHIA COLI; FED BATCH CULTURE; FERMENTATION; GLUCOSE INTAKE; GLUCOSE UTILIZATION; GROWTH INHIBITION; LIMIT OF DETECTION; PROCESS DEVELOPMENT; PROTEIN EXPRESSION;

ESCHERICHIA COLI;

AMINO ACIDS; ESCHERICHIA COLI; FERMENTATION; GLUCOSE; NORLEUCINE; OXYGEN; TRACE ELEMENTS; VALINE;

EID: 84887902017     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/1475-2859-12-116     Document Type: Article

References (34)

1. Kisumi M, Sugiura M, Kato J, Chibata I. L-Norvaline and L-homoisoleucine formation by Serratia marcescens. J Biochem 1976, 79(5):1021-1028.
2. Suguira M, Kisumi M, Chibata I. Biosynthetic pathway of beta-methylnorleucine, an antimetabolite produced by Serrati marcescens. J Antibiot 1981, 34:1283-1289. 10.7164/antibiotics.34.1283, 7031031.
3. Nandi P, Sen GP. An antifungal substance from a strain of Bacillus subtilis. Nature 1953, 172:871-872.
4. Apostol I, Levine J, Lippincott J, Leach J, Hess E, Glascock CB, Weickert MJ, Blackmore R. Incorporation of norvaline at leucine positions in recombinant human hemoglobin expressed in Escherichia coli. J Biol Chem 1997, 272:28980-28988. 10.1074/jbc.272.46.28980, 9360970.
5. Lu HS, Tsai LB, Kenney WC, Lai PH. Identification of unusual replacement of methionine by norleucine in recombinant interleukin-2 produced by E. coli. Biochem Biophys Res Commun 1988, 156:807-813. 10.1016/S0006-291X(88)80916-1, 3056404.
6. Tsai LB, Lu HS, Kenney WC, Curless CC, Klein ML, Lai PH, Fenton DM, Altrock BW, Mann MB. Control of misincorporation of de novo synthesized norleucine into recombinant interleukin-2 in E. coli. Biochem Biophys Res Commun 1988, 156:733-739. 10.1016/S0006-291X(88)80904-5, 3056402.
7. Sunasara KM, Cramer SM, Hauer CR, Rupp RG, Shoup VA. Characterization of recombinant human brain-derived neurotrophic factor variants. Arch Biochem Biophys 1999, 372(2):248-260. 10.1006/abbi.1999.1501, 10600162.
8. Bogosian G, Violand BN, Dorward-King EJ, Workman WE, Jung PE, Kane JF. Biosynthesis and incorporation into protein of norleucine by Escherichia coli. J Biol Chem 1998, 264:531-539.
9. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 2012, 11(7):527-540. 10.1038/nrd3746, 3714370, 22743980.
10. Ahmed I, Kaspar B, Sharma U. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther 2012, 34(2):400-419. 10.1016/j.clinthera.2011.12.005, 22244050.
11. Kurland C, Gallant J. Errors of heterologous protein expression. Curr Opin Biotechnol 1996, 7(5):489-493. 10.1016/S0958-1669(96)80050-4, 8939626.
12. Rosenberger RF. Translational errors during recombinant protein synthesis. Dev Biol Stand 1994, 83:21-26.
13. Yang Y, Strahan A, Li C, Shem A, Liu H, Ouyang J, Katta V, Francissen K, Zhang B. Detecting low level sequence variants in recombinant monoclonal antibodies. mAbs 2010, 2(3):285-289. 10.4161/mabs.2.3.11718, 2881255, 20400866.
14. Yu XC, Borisov OV, Alvarez M, Michels DA, Wang YJ, Ling V. Identification of codon-specific serine to asparagine mistranslation in recombinant monoclonal antibodies by high-resolution mass spectrometry. Anal Chem 2009, 81(22):9282-9290. 10.1021/ac901541h, 19852494.
15. Zeck A, Regula JT, Larraillet V, Mautz B, Popp O, Göpfert U, Wiegeshoff F, Vollertsen U, Gorr IH, Koll H, Papadimitriou A. Low Level Sequence Variant Analysis of Recombinant Proteins: an optimized approach. PLos One 2012, 7(7):e40328. 10.1371/journal.pone.0040328, 3391300, 22792284.
16. Reynolds NM, Lazazzera BA, Ibba M. Cellular mechanisms that control mistranslation. Nat Rev Microbiol 2010, 12:849-856.
17. Yadavalli SS, Ibba M. Selection of tRNA charging quality control mechanisms that increase mistranslation of the genetic code. Nucleic Acids Res 2013, 41(2):1104-1112. 10.1093/nar/gks1240, 3553970, 23222133.
18. Budisa N, Steipe B, Demange P, Eckerskorn C, Kellermann J, Huber R. High-level biosynthetic substitution of methionine in proteins by its analogs 2-aminohexanoic acid, selenomethionine, telluromethionine and ethionine in Escherichia coli. Eur J Biochem 1995, 230:788-796. 10.1111/j.1432-1033.1995.tb20622.x, 7607253.
19. Hoesl MG, Budisa N. Recent advances in genetic code engineering in Escherichia coli. Curr Opin Biotechnol 2012, 23:751-757. 10.1016/j.copbio.2011.12.027, 22237016.
20. Sycheva EV, Yampol'skaya TA, Preobrajenskaya ES, Novikova AE, Matrosov NG, Stoynova NV. Overproduction of noncanonical amino acids by Escherichia coli cells. Mikrobiologiya 2007, 76(6):805-812.
21. Soini J, Falschlehner C, Liedert C, Bernhardt J, Vuoristo J, Neubauer P. Norvaline is accumulated after a down-shift of oxygen in Escherichia coli W3110. Microb Cell Fact 2008, 7:30. 10.1186/1475-2859-7-30, 2579280, 18940002.
22. Kohlhaw G, Leary TR, Umbarger HE. Alpha-isopropylmalate synthase from Salmonella typhimurium. Purification and properties. J Biol Chem 1969, 244:2218-2225.
23. Soini J, Ukkonen K, Neubauer P. Accumulation of amino acids deriving from pyruvate in Escherichia coli W3110 during fed-batch cultivation in a two-compartment scale-down bioreactor. Adv Biosci Biotechnol 2011, 2:336-339.
24. Huang CJ, Lin H, Yang X. Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J Ind Microbiol Biotechnol 2012, 39(3):383-399. 10.1007/s10295-011-1082-9, 22252444.
25. Takors R. Scale-up of microbial processes: impacts, tools and open questions. J Biotechnol 2012, 160(1-2):3-9.
26. Neubauer P, Junne S. Scale-down simulators for metabolic analysis of large-scale bioprocesses. biotechnology 2010, 21(1):114-121.
27. Soini J, Ukkonen K, Neubauer P. High cell density media for Escherichia coli are generally designed for aerobic cultivations - consequences for large-scale bioprocesses and shake flask cultures. Microb Cell Fact 2008, 7:26. 10.1186/1475-2859-7-26, 2526063, 18687130.
28. Habicht G, Haupt C, Friedrich RP, Hortschansky P, Sachse C, Meinhardt J, Wieligmann K, Gellermann GP, Brodhun M, Götz J, Halbhuber KJ, Röcken C, Horn U, Fändrich M. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils. Proc Natl Acad Sci USA 2007, 104(49):19232-19237. 10.1073/pnas.0703793104, 2148273, 18042730.
29. Carneiro S, Ferreira EC, Rocha I. Metabolic responses to recombinant bioprocesses in Escherichia coli. J Biotechnol 2013, 164(3):396-408. 10.1016/j.jbiotec.2012.08.026, 23022453.
30. Trotter EW, Rolfe MD, Hounslow AM, Craven CJ, Williamson MP, Sanguinetti G, Poole RK, Green J. Reprogramming of Escherichia coli K-12 metabolism during the initial phase of transition from an anaerobic to a micro-aerobic environment. PLoS One 2011, 6(9):e25501. 10.1371/journal.pone.0025501, 3181329, 21980479.
31. Hewitt CJ, Onyeaka H, Lewis G, Taylor IW, Nienow AW. A comparison of high cell density fed-batch fermentations involving both induced and non-induced recombinant Escherichia coli under well-mixed small-scale and simulated poorly mixed large-scale conditions. Biotechnol Bioeng 2007, 96(3):495-505. 10.1002/bit.21127, 16902956.
32. Beyer L, Doberenz C, Falke D, Hunger D, Suppmann B, Sawers RG. Coordination of FocA and pyruvate formate-lyase synthesis in Escherichia coli demonstrates preferential translocation of formate over other mixed-acid fermentation products. J Bacteriol 2013, 195(7):1428-1435. 10.1128/JB.02166-12, 3624525, 23335413.
33. Pinske C, Bönn M, Krüger S, Lindenstrauß U, Sawers RG. Metabolic deficiences revealed in the biotechnologically important model Bacterium Escherichia coli BL21(DE3). PLos One 2011, 6(8):e22830. 10.1371/journal.pone.0022830, 3149613, 21826210.
34. Biermann M, Bardl B, Vollstädt S, Linnemann J, Knüpfer U, Seidel G, Horn U. Simultaneous analysis of the non-canonical amino acids norleucine and norvaline in biopharmaceutical-related fermentation processes by a new ultra-high performance liquid chromatography approach. Amino Acids 2013, 44(4):1225-1231. 10.1007/s00726-013-1459-3, 3597275, 23306451.